

Special Issue

Cancer Metastasis in 2025–2026

Message from the Guest Editor

The topic of this Special Issue is cancer metastasis, the lethal aspect of malignant neoplasms. Recently, there has been a surge of discoveries addressing critical mechanistic questions about individual steps within the complicated process of metastasis. Nevertheless, there is much we do not know about this insidious property of cancer. For this Special Issue, we broadly invite investigators to submit original research articles, or opinion pieces, on any aspect of metastasis biology or the clinical treatment of metastasis. Example topics include (but are not limited to) the following: (a) transition from pre-malignant to invasive cancer, (b) molecular mechanisms of invasion and cancer cell plasticity, (c) immune cooperation/suppression of metastasis, (d) lymphatic versus hematogenous spread, tumor suppression of the draining lymph node, (e) extravasation and circulating tumor cells, (f) clonal evolution and stem-like cells in metastasis, (g) bone metastasis, (h) personalized treatment of metastasis, (i) dormancy of metastasis, (j) exosome biology and metastasis, (k) clinical detection of metastasis, and (l) immunotherapy of metastasis.

Guest Editor

Prof. Dr. Lance A. Liotta

Department of Systems Biology, Center for Applied Proteomics and Molecular Medicine, George Mason University, 10900 University Boulevard, MS 4E3, Manassas, VA 20110, USA

Deadline for manuscript submissions

31 July 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/254775

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)